Search

Your search keyword '"Ansell, Pete"' showing total 16 results
Start Over Author "Ansell, Pete"
16 results on '"Ansell, Pete"'

1. Towards Hardware-Agnostic Gaze-Trackers

Author

Sharma, Jatin, Campbell, Jon, Ansell, Pete, Beavers, Jay, and O'Dowd, Christopher

Subjects
Computer Science - Artificial Intelligence, Computer Science - Computer Vision and Pattern Recognition, Computer Science - Human-Computer Interaction, Computer Science - Machine Learning
Abstract

Gaze-tracking is a novel way of interacting with computers which allows new scenarios, such as enabling people with motor-neuron disabilities to control their computers or doctors to interact with patient information without touching screen or keyboard. Further, there are emerging applications of gaze-tracking in interactive gaming, user experience research, human attention analysis and behavioral studies. Accurate estimation of the gaze may involve accounting for head-pose, head-position, eye rotation, distance from the object as well as operating conditions such as illumination, occlusion, background noise and various biological aspects of the user. Commercially available gaze-trackers utilize specialized sensor assemblies that usually consist of an infrared light source and camera. There are several challenges in the universal proliferation of gaze-tracking as accessibility technologies, specifically its affordability, reliability, and ease-of-use. In this paper, we try to address these challenges through the development of a hardware-agnostic gaze-tracker. We present a deep neural network architecture as an appearance-based method for constrained gaze-tracking that utilizes facial imagery captured on an ordinary RGB camera ubiquitous in all modern computing devices. Our system achieved an error of 1.8073cm on GazeCapture dataset without any calibration or device specific fine-tuning. This research shows promise that one day soon any computer, tablet, or phone will be controllable using just your eyes due to the prediction capabilities of deep neutral networks.

Published
2020

3. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, de Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, Golfinopoulos, Vassilis, van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, de Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, and Golfinopoulos, Vassilis

Published
2021

4. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

MS Medische Oncologie, Cancer, van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, de Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, Golfinopoulos, Vassilis, MS Medische Oncologie, Cancer, van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, de Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, and Golfinopoulos, Vassilis

Published
2021

5. Estrogen receptor-independent catechol estrogen binding activity: protein-binding studies in wild-type, estrogen receptor-alpha KO, and aromatase KO mice tissues

Author

Philips, Brain J., Ansell, Pete J., Newton, Leslie G., Harada, Nobuhira, Honda, Shin-Ichiro;, Ganjam, Venkataseshu K, Rottinghaus, George E, Welshons, Wade V., and Lubahn, Dennis B.

Subjects
Estrogen -- Research, Estrogen -- Chemical properties, Protein binding -- Research, Biological sciences, Chemistry
Abstract

A research was chemically designed to biochemically characterize the protein(s) that could be mediating the biological effects of catechol estrogens using enzymatically synthesized, radiolabeled 4-hydroxyestrone (4OHE1) and 4OHE2. Results from their studies demonstrated oxidative metabolism of this radiolabeled compound under normal binding assay conditions.

Published
2004

6. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

van den Bent, Martin, primary, Eoli, Marica, additional, Sepulveda, Juan Manuel, additional, Smits, Marion, additional, Walenkamp, Annemiek, additional, Frenel, Jean-Sebastian, additional, Franceschi, Enrico, additional, Clement, Paul M, additional, Chinot, Olivier, additional, de Vos, Filip, additional, Whenham, Nicolas, additional, Sanghera, Paul, additional, Weller, Michael, additional, Dubbink, H J, additional, French, Pim, additional, Looman, Jim, additional, Dey, Jyotirmoy, additional, Krause, Scott, additional, Ansell, Pete, additional, Nuyens, Sarah, additional, Spruyt, Maarten, additional, Brilhante, Joana, additional, Coens, Corneel, additional, Gorlia, Thierry, additional, and Golfinopoulos, Vassilis, additional

Published
2020
Full Text
View/download PDF

7. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

Van Den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, De Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, Golfinopoulos, Vassilis, Van Den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, De Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, and Golfinopoulos, Vassilis

Abstract

BACKGROUND: Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody-drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma. METHODS: Eligible were patients with centrally confirmed EGFR amplified glioblastoma at first recurrence after chemo-irradiation with temozolomide. Patients were randomized to either Depatux-M 1.25 mg/kg every 2 weeks intravenously, or this treatment combined with temozolomide 150-200 mg/m2 day 1-5 every 4 weeks, or either lomustine or temozolomide. The primary endpoint of the study was overall survival. RESULTS: Two hundred sixty patients were randomized. In the primary efficacy analysis with 199 events (median follow-up 15.0 mo), the hazard ratio (HR) for the combination arm compared with the control arm was 0.71 (95% CI = 0.50, 1.02; P = 0.062). The efficacy of Depatux-M monotherapy was comparable to that of the control arm (HR = 1.04, 95% CI = 0.73, 1.48; P = 0.83). The most frequent toxicity in Depatux-M treated patients was a reversible corneal epitheliopathy, occurring as grades 3-4 adverse events in 25-30% of patients. In the long-term follow-up analysis with median follow-up of 28.7 months, the HR for the comparison of the combination arm versus the control arm was 0.66 (95% CI = 0.48, 0.93). CONCLUSION: This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant temozolomide treatment. (NCT02343406).

Published
2020

8. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study

Author

Baxter, Patricia A, primary, Su, Jack M, primary, Onar-Thomas, Arzu, primary, Billups, Catherine A, primary, Li, Xiao-Nan, primary, Poussaint, Tina Young, primary, Smith, Edward R, primary, Thompson, Patrick, primary, Adesina, Adekunle, primary, Ansell, Pete, primary, Giranda, Vincent, primary, Paulino, Arnold, primary, Kilburn, Lindsey, primary, Quaddoumi, Ibrahim, primary, Broniscer, Alberto, primary, Blaney, Susan M, primary, Dunkel, Ira J, primary, and Fouladi, Maryam, primary

Published
2020
Full Text
View/download PDF

9. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

Van Den Bent, Martin, primary, Eoli, Marica, primary, Sepulveda, Juan Manuel, primary, Smits, Marion, primary, Walenkamp, Annemiek, primary, Frenel, Jean-Sebastian, primary, Franceschi, Enrico, primary, Clement, Paul M, primary, Chinot, Olivier, primary, De Vos, Filip, primary, Whenham, Nicolas, primary, Sanghera, Paul, primary, Weller, Michael, primary, Dubbink, H J, primary, French, Pim, primary, Looman, Jim, primary, Dey, Jyotirmoy, primary, Krause, Scott, primary, Ansell, Pete, primary, Nuyens, Sarah, primary, Spruyt, Maarten, primary, Brilhante, Joana, primary, Coens, Corneel, primary, Gorlia, Thierry, primary, and Golfinopoulos, Vassilis, primary

Published
2019
Full Text
View/download PDF

10. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Author

Bent, Martin Van Den, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, Vos, Filip De, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, and Nuyens, Sarah

Published
2020
Full Text
View/download PDF

12. Estrogen Receptor-Independent Catechol Estrogen Binding Activity: Protein Binding Studies in Wild-Type, Estrogen Receptor-α KO, and Aromatase KO Mice Tissues

Author

Philips, Brian J., primary, Ansell, Pete J., additional, Newton, Leslie G., additional, Harada, Nobuhiro, additional, Honda, Shin-Ichiro, additional, Ganjam, Venkataseshu K., additional, Rottinghaus, George E., additional, Welshons, Wade V., additional, and Lubahn, Dennis B., additional

Published
2004
Full Text
View/download PDF

15. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Author

van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, de Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, and Golfinopoulos V

Published
2021
Full Text
View/download PDF

16. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Author

Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, and Golfinopoulos V

Subjects
Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Alkylating therapeutic use, ErbB Receptors genetics, Humans, Lomustine therapeutic use, Temozolomide therapeutic use, Brain Neoplasms drug therapy, Glioblastoma drug therapy
Abstract

Background: Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody-drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma., Methods: Eligible were patients with centrally confirmed EGFR amplified glioblastoma at first recurrence after chemo-irradiation with temozolomide. Patients were randomized to either Depatux-M 1.25 mg/kg every 2 weeks intravenously, or this treatment combined with temozolomide 150-200 mg/m2 day 1-5 every 4 weeks, or either lomustine or temozolomide. The primary endpoint of the study was overall survival., Results: Two hundred sixty patients were randomized. In the primary efficacy analysis with 199 events (median follow-up 15.0 mo), the hazard ratio (HR) for the combination arm compared with the control arm was 0.71 (95% CI = 0.50, 1.02; P = 0.062). The efficacy of Depatux-M monotherapy was comparable to that of the control arm (HR = 1.04, 95% CI = 0.73, 1.48; P = 0.83). The most frequent toxicity in Depatux-M treated patients was a reversible corneal epitheliopathy, occurring as grades 3-4 adverse events in 25-30% of patients. In the long-term follow-up analysis with median follow-up of 28.7 months, the HR for the comparison of the combination arm versus the control arm was 0.66 (95% CI = 0.48, 0.93)., Conclusion: This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant temozolomide treatment. (NCT02343406)., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results